(Q34677200)

3 August 2017

title

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection (English)

1 reference

3 August 2017

0 references

1 reference

Hans Lilja

4

0 references

Andrew Vickers

object named as

Andrew J Vickers

series ordinal

1

0 references

Catherine M Tangen

series ordinal

3

object named as

Catherine M Tangen

1 reference

3 August 2017

Cathee Till

2

1 reference

3 August 2017

Ian M Thompson

series ordinal

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

24 February 2011

1 reference

Journal of the National Cancer Institute

3 August 2017

published in

1 reference

3 August 2017

volume

103

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

462-469

1 reference

NCCN clinical practice guidelines in oncology: prostate cancer early detection

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Prostate specific antigen best practice statement: 2009 update.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Outcomes of localized prostate cancer following conservative management

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

7 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Screening and prostate-cancer mortality in a randomized European study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Radical prostatectomy versus watchful waiting in early prostate cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

The influence of finasteride on the development of prostate cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057983

Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened P

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR028

Implementation of the Prostate Cancer Prevention Trial (PCPT).

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR028

Mathematical rigor is necessary, but for men with prostate cancer, clinical relevance is the priority

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR028

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21350221

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JNCI/DJR028

1 reference

3 August 2017

1 reference

3 August 2017

1 reference